Core Insights - Biomerica, Inc. has received its first commercial order for its Hp Detect™ diagnostic stool antigen test from a major clinical laboratory chain in Europe, specifically for the UK market [1][2][4] - This order signifies a crucial step in the commercialization of Hp Detect™ across Europe, with potential for future distribution discussions in the broader EU market [2][3] - The product's performance has met the rigorous standards of the professional laboratory market, enhancing Biomerica's position for additional distribution relationships in both the US and Europe [3][4] Commercial Significance - The order from a leading clinical laboratory network in Europe is expected to serve as a reference account, facilitating broader adoption of Hp Detect™ in the EU laboratory channel [2][7] - Biomerica anticipates that this initial order will lead to recurring orders as Hp Detect™ becomes integrated into the customer's routine testing workflow [4][7] Market Opportunity - H. pylori is a prevalent bacterial infection, affecting an estimated 45% of the population in Europe's five largest countries, and is recognized as a Class 1 carcinogen by the WHO [4][5][7] - The WHO lists H. pylori among the 16 antibiotic-resistant bacteria that pose significant threats to human health, underscoring the need for accurate diagnostics [4][7] Regulatory Context - Hp Detect™ received registration from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in February 2026, allowing for its commercial use in the UK [1][4] - The National Health Service (NHS) in the UK recommends testing and treating H. pylori in patients with gastrointestinal symptoms, creating a consistent demand for diagnostic products like Hp Detect™ [5][7]

Core Viewpoint - Biomerica, Inc. has received official registration from the UK Medicines & Healthcare products Regulatory Agency (MHRA) for its hp+detect™ diagnostic test, which detects Helicobacter pylori (H. pylori) bacteria, allowing it to be marketed in the UK [1][4] Group 1: Product and Market Impact - The hp+detect™ product detects H. pylori, which infects approximately 35% of the U.S. population and 45% of the population in Europe's five largest countries, and is a significant risk factor for gastric cancer [2][3] - H. pylori is responsible for peptic ulcer disease and is a primary driver of gastric cancer, which is the third most common cause of cancer-related death globally [3] - The WHO has classified H. pylori as a Class 1 carcinogen and among the 16 antibiotic-resistant bacteria that pose a major threat to human health, highlighting the need for accurate diagnostic tools [2][6] Group 2: Commercial Strategy and Future Plans - The MHRA registration is a significant commercial milestone for Biomerica, expanding its international reach into the UK market, which is important due to the high prevalence of H. pylori infection in Europe [4][6] - The company is actively engaging with UK partners to penetrate the diagnostic laboratory market and anticipates providing updates as agreements are finalized [6]

Core Insights - Biomerica, Inc. announced positive responder analysis results from its real-world study of inFoods® IBS, showing significant reductions in abdominal pain and bloating among patients with Irritable Bowel Syndrome (IBS) [2][12] Responder Analysis - The study involved 69 patients, with 59.4% achieving a ≥30% reduction in abdominal pain and 68.1% achieving a ≥30% reduction in bloating, using FDA-recognized responder endpoints [7][8] - Mean abdominal pain scores decreased from 3.24 to 2.12 (34.6% reduction, P = 0.0002) and mean bloating scores declined from 4.35 to 2.54 (41.7% reduction, P < 0.0001) [8] Consistency with Peer-Reviewed Controlled Trial - The real-world responder rate of 59.4% for abdominal pain closely aligns with the 59.6% rate from a peer-reviewed randomized controlled trial published in Gastroenterology, indicating strong consistency in clinical outcomes [5][4] Commercial Milestones - A national Medicare payment rate of $300 for the inFoods® IBS test was established, effective January 1, 2026, which the company will use as a benchmark for negotiations with private insurers [9] - The American Medical Association approved a unique CPT® PLA code for inFoods® IBS, effective October 1, 2025, simplifying billing processes [10] Market Opportunity - IBS affects approximately 30 to 45 million adults in the U.S., representing 10%-15% of the adult population, leading to decreased quality of life and reliance on medications with adverse side effects [13] - inFoods® IBS offers a precision diagnostic approach that identifies individual food triggers, addressing a significant unmet clinical need within an estimated $30 billion total addressable market [14]

Core Insights - Biomerica, Inc. has received approval from Vietnam's Hanoi Department of Health for its EZ Detect™ colorectal disease at-home screening test, marking a significant step in the company's global expansion into Southeast Asia [1][2][11] Group 1: Product Overview - EZ Detect™ is an FDA-cleared two-minute at-home screening test designed to detect early warning signs of colorectal cancer and other colorectal diseases [2][7] - The test identifies occult blood in stool, which is a critical early indicator of colorectal diseases, including cancer [8] - The test is user-friendly, requiring no special preparation or handling of stool, and can be completed privately at home [8][9] Group 2: Market Opportunity - Colorectal cancer is a significant public health issue in Vietnam, with 16,835 new cases reported in 2022, making it the fourth most common cancer in the country [3] - The five-year survival rate for colorectal cancer in Vietnam is only 45%, compared to 91% in the United States when detected early [3][10] - The global market for colorectal cancer screening is substantial, with approximately 1.93 million new cases and over 900,000 deaths worldwide in 2022, and these figures are expected to rise significantly by 2050 [5] Group 3: Strategic Importance - The approval of EZ Detect™ represents a milestone for Biomerica's strategic entry into Southeast Asia's rapidly growing healthcare market, which has over 680 million people and increasing healthcare spending [2][11] - The company aims to work with a major healthcare distributor in Vietnam to ensure widespread availability of the product through various sales channels [1][11] - This approval serves as a template for potential expansion into other Southeast Asian markets, emphasizing the importance of accessible at-home screening tests [11]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - Biomerica, Inc. reported financial results for the second quarter of fiscal 2026, highlighting a strategic shift towards higher-margin diagnostic-guided therapy products and the commercialization of its inFoods IBS test [1][6]. Financial Performance - Net sales for the second quarter of fiscal 2026 were $1.21 million, down from $1.64 million in the prior year, primarily due to the absence of large initial distributor orders in the MENA region [9]. - For the six months ended November 30, 2025, net sales were $2.59 million, compared to $3.44 million in the prior year period [10]. - Gross margin for the six-month period was 18%, down from 21% in the prior year, reflecting the transition to higher-margin products [10]. - Operating expenses for the second quarter were $1.42 million, slightly down from $1.43 million in the same period last year [11]. - The net loss for the second quarter was $1.32 million, compared to $0.95 million in the prior year quarter, while the net loss for the six months improved to $1.31 million from $2.27 million in the prior year [12]. Strategic Developments - Biomerica entered a marketing services agreement with Henry Schein to support the commercialization of the inFoods IBS test in the U.S., enhancing awareness among healthcare providers [2]. - The company launched the AI-backed inFoods IBS Trigger Food Navigator, designed to improve dietary compliance for IBS patients by providing personalized meal suggestions [3]. - The Centers for Medicare & Medicaid Services established a national Medicare payment rate of $300 for the inFoods IBS test, effective January 1, 2026, which is expected to enhance patient access [4]. - The Egyptian Drug Authority authorized Biomerica's complete screening test portfolio, facilitating international expansion of its diagnostic products [5]. Management Commentary - The CEO emphasized a strategic pivot from lower-margin products to higher-value diagnostic-guided therapy products, indicating that current revenue softness is a result of this transition rather than a decline in business fundamentals [6]. - The CFO noted a 27% reduction in research and development expenses while continuing to invest in high-value diagnostic programs, indicating a focus on operational efficiency [8].

Financial Performance - Consolidated net sales for the three months ended November 30, 2025, were approximately $1,210,000, a decrease of 26% compared to $1,636,000 for the same period in 2024[41] - For the six months ended November 30, 2025, consolidated net sales were approximately $2,590,000, down 25% from $3,444,000 for the same period in 2024[41] - Gross profit for the three months ended November 30, 2025, was $51,000, down from $437,000 in the same period of 2024, indicating a significant decline in profitability[81] - The company reported a net loss of $1,320,000 for the three months ended November 30, 2025, compared to a net loss of $950,000 for the same period in 2024[81] - Total operating expenses for the six months ended November 30, 2025, were $2,966,000, slightly down from $3,087,000 in 2024[81] - For the three months ended November 30, 2025, total revenues were $1,210,000, a decrease from $1,636,000 in the same period of 2024, representing a decline of approximately 26%[90] - For the six months ended November 30, 2025, total revenues were $2,590,000, down from $3,444,000 in the same period of 2024, indicating a decrease of about 25%[90] Cash and Assets - As of November 30, 2025, the company had an accumulated deficit of approximately $54,486,000 and cash and cash equivalents of approximately $2,543,000[31] - As of November 30, 2025, total gross receivables were approximately $1,043,000, with four key customers accounting for 75% of gross accounts receivable[43] - Net inventory as of November 30, 2025, was approximately $1,524,000, with inventory reserves recorded at approximately $434,000[52] - The company had approximately $30,000 in advances from domestic customers as of November 30, 2025, representing prepayments for future shipments[69] - As of November 30, 2025, the company had approximately $469,000 of gross inventory located in Mexicali, Mexico[90] Financing and Investments - The company sold 391,125 shares of common stock during the six months ended November 30, 2025, resulting in gross proceeds of approximately $1,432,000[33] - The company intends to use net proceeds from the 2024 ATM Offering for general corporate purposes, including sales and marketing activities, clinical studies, and product development[34] - The company invested approximately $165,000 into a privately held Polish distributor, owning approximately 6% of the distributor[59] - The company filed a Shelf Registration allowing the issuance of up to $20,000,000 in common stock, with a prospectus supplement filed for $5,500,000 through the 2024 ATM Offering[88] - During the six months ended November 30, 2025, the company sold 391,125 shares at prices ranging from $3.34 to $4.02, resulting in gross proceeds of approximately $1,432,000 and net proceeds of $1,395,000 after expenses[89] Operational Challenges - The company has incurred net losses and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern[35] - The company is actively pursuing strategies to increase sales, reduce expenses, and seek additional financing to address capital needs[37] Expenses and Costs - Share-based compensation expenses for the six months ended November 30, 2025, were approximately $145,000, a decrease of 37.5% from $232,000 in 2024[64] - Research and development costs for the three months ended November 30, 2025, were $193,000, compared to $257,000 for the same period in 2024, reflecting a reduction of 25%[72] - The company reported operating lease costs of $88,000 for both the three months ended November 30, 2025, and 2024, with total lease costs remaining consistent at $93,000[97] Legal and Compliance - There were no material legal proceedings pending as of November 30, 2025, indicating a stable legal environment for the company[100] - The company is currently evaluating the impact of new accounting standards issued by the FASB on its financial statements and disclosures[86][87] Stock Options - The weighted average exercise price of options outstanding as of November 30, 2025, was $17.85, reflecting a change from $19.29 at the beginning of the period[64] - The total number of options outstanding increased to 444,708 as of November 30, 2025, from 413,866 at the end of May 2025[64] - The weighted-average remaining lease term as of November 30, 2025, was 0.77 years, with a weighted-average discount rate of 6.50%[98]

Core Insights - Biomerica, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has set a national Medicare payment rate of $300 for its inFoods® IBS test, effective January 1, 2026, under the Clinical Laboratory Fee Schedule (CLFS) [1][9] - The establishment of a dedicated CPT® Proprietary Laboratory Analyses (PLA) code for inFoods® IBS, effective October 1, 2025, enhances the test's market position and patient access [2] Commercial Milestone - The $300 payment rate from CMS provides a foundation for negotiations with private insurers, as CMS is the largest payer in the U.S. healthcare system, accounting for approximately 21% of total healthcare expenditure [3][9] - The CEO of Biomerica emphasized that the pricing determination is a significant milestone for both the company and patients suffering from IBS, positioning the company for commercial growth in 2026 and beyond [4] Market Need - Irritable bowel syndrome (IBS) affects about 10% to 15% of adults in the U.S., translating to over 30 million potential patients, highlighting a significant unmet medical need [4] - Current treatment options for IBS often provide inconsistent relief and may involve side effects, with no FDA-approved drugs for the IBS-M subtype, which represents about one-third of the IBS market [4] Product Efficacy - The inFoods® IBS test utilizes a personalized diagnostic approach to identify food triggers for IBS symptoms, allowing for targeted dietary recommendations [5] - Clinical trials demonstrated that 59.6% of patients who eliminated identified trigger foods met the FDA-standard target for abdominal pain reduction, compared to 42.2% in the control group [6] - Notable efficacy was observed in difficult-to-treat populations, with 67.1% of IBS-C patients and 66% of IBS-M patients achieving FDA-target pain reduction [7] Strategic Positioning - The combination of clinical evidence, a dedicated PLA code, and a national CLFS price represents a pivotal moment for inFoods® IBS [8] - The company plans to work with Medicare Administrative Contractors to secure coverage for the inFoods® IBS test and leverage the established pricing to negotiate with private insurers [10] Value Proposition - The CMS pricing announcement enhances Biomerica's market opportunity by providing a differentiated offering, a large patient population, a personalized medicine approach, and platform potential for additional gastrointestinal conditions [11]

Core Insights - Biomerica, Inc. has received authorization from the Egyptian Drug Authority for its complete portfolio of rapid diagnostic tests, enhancing access to early detection tools for cancer and chronic diseases in Egypt [1][2][10] Product Portfolio - The authorized screening tests include those for colorectal disease, breast self-examination, prostate disease, kidney disease, and H. pylori infection, all designed for point-of-care use [1][3][7] - Tests provide quick results within minutes and do not require laboratory sample processing, making them suitable for diverse clinical and community settings [3][14] Market Need - Colorectal cancer is the 7th most common cancer in Egypt, with an incidence of approximately 5 to 10 cases per 100,000 persons per year, and a concerning trend of late-stage diagnoses [4] - Breast cancer is the most common cancer among women in Egypt, with an age-standardized incidence rate of about 55.4 per 100,000 persons per year, and poorer mortality outcomes due to late-stage diagnosis [5] - Prostate cancer ranks as the fourth most common cancer in Egypt, with increasing incidence rates [6] Health Statistics - Approximately 13% of adults in Egypt are living with chronic kidney disease, which has been among the top five causes of death from 2009 to 2019 [8] - H. pylori infection prevalence in Egypt ranges from 50% to 70%, affecting a significant portion of the population [8] Strategic Impact - The authorization supports national public health efforts to improve early disease detection, enhance health outcomes, and reduce long-term healthcare costs [9][10] - Biomerica's expansion in the Middle East and North Africa (MENA) region is reinforced by this authorization, aligning with global preventive care trends [11]

Core Insights - Biomerica, Inc. has announced the publication of a large multicenter clinical trial demonstrating the effectiveness of its inFoods® IBS diagnostic-guided therapy in managing Irritable Bowel Syndrome (IBS) symptoms [1][3][10] Study Overview - The clinical trial was randomized, multicenter, double-blind, and placebo-controlled, evaluating the inFoods® IBS test's ability to identify patient-specific dietary triggers and guide targeted food elimination [2][4] - The study involved 223 IBS patients across eight major U.S. academic medical centers, including renowned institutions like Mayo Clinic and Harvard Beth Israel Deaconess Medical Center [4] Key Findings - Patients following the inFoods® IBS-guided elimination diet experienced significantly greater symptom relief, with 59.6% achieving the FDA-defined target for abdominal pain reduction compared to 42.1% in the control group [9] - Particularly strong results were noted in difficult-to-treat IBS subtypes, with 67.1% of IBS-C patients and 66.0% of IBS-M patients responding positively to the treatment [9] Methodology and Innovation - The inFoods® IBS assay utilizes a proprietary discriminatory p-value method to identify foods causing abnormal IgG responses unique to IBS patients, allowing for a more focused dietary approach [7][10] - The study design addressed limitations of previous research by employing an IBS-specific food panel and robust statistical methodology, enhancing the reliability of the findings [6][10] Clinical Implications - The results support a shift towards precision medicine in gastrointestinal care, where individualized biological markers guide tailored treatment decisions rather than generalized approaches [12][11] - The inFoods® IBS protocol typically results in the elimination of only 2 to 4 foods per patient, making it a more practical and sustainable option compared to broader dietary strategies like the low-FODMAP diet [8][10] Recognition and Future Outlook - The inclusion of inFoods® IBS in Biotherapeutics Quarterly highlights the growing recognition of Biomerica's innovation among healthcare professionals [13] - The study's outcomes underscore the potential of diagnostic-guided dietary strategies to address unmet clinical needs, particularly for IBS-M patients, for whom no FDA-approved medications currently exist [11][12]